The partnership between NewBiologix and Synastra Biotechnology marks a significant advancement in the production of gene therapies, particularly for Duchenne muscular dystrophy (DMD). Headquartered in Switzerland, NewBiologix has entered into an agreement with the Turkish company Synastra, which was formed through a collaboration involving Üsküdar University and Unifon-Biotech GSYF Venture Capital Investment Fund.
Innovative Manufacturing Solutions
NewBiologix will employ its Xcell™ stable manufacturing platform to create and characterize a research cell bank for Synastra’s DMD gene therapy candidate. This agreement not only focuses on research but also includes an option for future commercial licensing, facilitating the transition to large-scale clinical manufacturing as the therapy progresses.
The collaboration synergizes Synastra’s strengths in genomic engineering, AAV vector design, and rare-disease gene therapy with NewBiologix’s proprietary cell engineering and rAAV manufacturing technologies. By tackling manufacturing challenges early in the development process, both companies aim to establish a reliable, reproducible, and scalable production system. This system is crucial for advancing the therapy toward clinical trials and eventual commercial distribution.
Understanding Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a serious, progressive neuromuscular disorder that predominantly affects males, with an incidence of about one in 5,000 births. The disease arises from mutations in the DMD gene, which disrupt the production of dystrophin, a protein essential for muscle function. This deficiency leads to the gradual degeneration of skeletal and cardiac muscles, resulting in severe health complications.
The Importance of Manufacturing in Gene Therapy
In the realm of gene therapies, particularly for DMD, manufacturing plays a pivotal role. Gene therapies often require substantial vector doses for systemic treatment, making factors like rAAV productivity, consistency, scalability, and cost critical for the successful development and widespread availability of these therapies.
NewBiologix’s Xcell platform addresses these manufacturing constraints head-on. As Dr. Igor Fisch, the company’s CEO and co-founder, highlights, the traditional method of transient transfection is complex, expensive, and difficult to scale reliably.
A Forward-Thinking Approach
Dr. Fisch asserts that the evolution of manufacturing processes is essential for gene therapy to reach its full potential. He emphasizes that DMD exemplifies the challenges faced in this area, as effective treatment necessitates large amounts of rAAV vector. With Xcell, NewBiologix integrates manufacturing considerations from the beginning of therapy development, utilizing stable, genetically engineered producer cell lines that minimize complexity and variability.
Strategic Vision from Synastra
Cihan Tastan, PhD, deputy chairman of the board and general manager of Synastra, shares the vision behind their collaboration. He explains that Synastra aims to leverage Turkey’s capabilities in genomic engineering to create competitive gene therapies for rare genetic disorders. Their investigational AAV-based micro-dystrophin candidate for DMD is being developed with a focus on establishing a comprehensive scientific, manufacturing, and translational pathway from the outset.
Bridging Design and Production
The collaboration effectively connects construct design with preclinical development and scalable rAAV manufacturing. By aligning these critical components, NewBiologix and Synastra are poised to make significant strides in the field of gene therapy, particularly for rare diseases like DMD.
Conclusion
The partnership between NewBiologix and Synastra is a promising step forward in the quest to provide effective gene therapies for Duchenne muscular dystrophy. By focusing on innovative manufacturing solutions and integrating production with therapy development, both companies are paving the way for more accessible and efficient treatments. This collaboration not only enhances the potential for successful clinical outcomes but also sets a precedent for future advancements in gene therapy.
- NewBiologix and Synastra are collaborating to enhance rAAV manufacturing for DMD.
- The agreement includes options for commercial licensing, facilitating future manufacturing.
- Duchenne muscular dystrophy is a severe neuromuscular disorder affecting males.
- Effective gene therapy requires scalable and consistent manufacturing processes.
- The partnership aims to integrate manufacturing considerations from the early stages of therapy development.
Read more → www.genengnews.com